-
One of the clearest outcomes of the 2012 election is that the Affordable Care Act (ACA), better known as Obamacare, has survived the last major threat to its existence.
-
Unscheduled spotting and bleeding occurs in 30% to 50% of women in the first few months of combined oral contraceptive (OC) use.1 How can you help patients stay the course?
-
Get ready to add new information to your contraceptive clinical dataset.
-
In discussing birth control options with a patient, she tells you she is interested in taking the Pill, but is concerned that it might be dangerous due to all the risks. Whats your next move?
-
Family planners now have proof positive that the intrauterine device (IUD) and the contraceptive implant, two long-acting reversible contraceptives (LARC methods), are superior in their effectiveness, compared to the effectiveness of the contraceptive pill, patch, or ring.
-
Review the records of the girls who have received at least one injection in the three-series vaccination series for human papillomavirus (HPV). How many have completed the series? If new research is any indication, the proportion of those receiving all three shots is low.
-
The Centers for Disease Control and Prevention (CDC) has a free webinar of its recent Public Health Grand Rounds, "The Growing Threat of Multidrug-Resistant Gonorrhea, available on its web site.
-
Family planning clinicians are familiar with the injectable contraceptive depot medroxyprogesterone acetate (DMPA) as an effective form of reversible birth control, following only the contraceptive implant and intrauterine device (IUD) in contraceptive efficacy.
-
Results from a multi-country clinical trial of a combined oral contraceptive (OC) containing nomegestrol acetate and 17-beta estradiol indicate it is an effective pill with good cycle control.
-
As of this writing, in mid-May, policymaking at the federal level was at a standstill, with lawmakers waiting on two major events: the Supreme Court's June decision on the Affordable Care Act and the November national elections. So, for this month's column, we'll turn our attention to the state level, where policymakers are having another busy year.
